Skip to content
InMed-logo-01
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
Menu
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
TSX_Logo
NASDAQ_Logo

Investor

ARTICLES

Lorem Ipsum

In ut turpis feugiat, pellentesque sapien ut, bibendum urna. Sed a erat tincidunt, auctor ex ut, facilisis est. Mauris tristique lacinia vulputate.

  • May 9, 2018
  • , 4:11 pm

Unlocking the potential of Cannabinoid Medicines

The cannabis plant naturally produces 90+ individual cannabinoid drugs. The human body has a natural, extensive ‘endocannabinoid’ receptor system located in the mammalian brain, throughout the central and peripheral nervous systems, and in tissues and organs. This system is predisposed to interact with members of the cannabinoid drug family. Despite the medical potential of these 90+ other cannabinoids, their role in treating disease remains largely unexplored.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Related Events & Webcasts

Presentation 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porttitor iaculis nulla, quis bibendum lacus semper a. Pellentesque vel malesuada enim. Integer sollicitudin nibh id

Read More
May 9, 2018

Presentation 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porttitor iaculis nulla, quis bibendum lacus semper a. Pellentesque vel malesuada enim. Integer sollicitudin nibh id

Read More
May 9, 2018

Events and Webcasts 3

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porttitor iaculis nulla, quis bibendum lacus semper a. Pellentesque vel malesuada enim. Integer sollicitudin nibh id

Read More
May 4, 2018

Stay Up to Date

Get all the latest news & information about InMed.

join our email list
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4
Science
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • IntegraSyn™ Cannabinoid Manufacturing
  • InMed’s Research of Rare Cannabinoids

Investor

  • News Releases
  • Latest Presentation
  • Letter to Shareholders
  • SEDAR® Filings
  • Financial Reports
  • Sign up for Investor Alerts

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Governance
  • Partners and Collaborators
  • Events Calendar
  • Careers

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2021 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On: